We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genomic Analysis for Diagnosing Trauma

By Biotechdaily staff writers
Posted on 31 Mar 2005
A recent publication described the first steps being taken to establish a network for the diagnosis of trauma victims through genomic analysis.

"It has been clear for approximately two decades that critical injury can trigger the release of immune factors that cause massive inflammation, and this can sometimes overwhelm the body's ability to cope,” said first author Dr. More...
J. Perren Cobb, associate professor of surgery and of genetics at Washington University School of Medicine (St. Louis, MO; USA). "We have produced a great deal of insight into how those inflammatory responses are generated, and we have tried a number of strategies to block or weaken them, but so far we have had relatively little success.”

A national collaborative effort called the Inflammation and Host Response to Injury Large Scale Collaboration Program, comprising more than 70 physicians and research scientists, was instituted to determine whether commercially available microarray technology could be used to measure changes in gene activity brought about by severe trauma. Blood samples and skeletal muscle from 34 severely injured patients and 23 healthy individuals were analyzed.


Results published in the March 29, 2005, issue of the Proceedings of the [U.S.] National Academy of Sciences showed that blood leukocyte gene expression in the same individual over a 24-hour period was remarkably constant. In contrast, genome-wide expression varied significantly among different subjects and leukocyte subpopulations.
Traumatic injury induced dramatic changes in apparent gene expression that were greater in magnitude than the analytic noise and variance among individuals.

The current study showed that by paying careful attention to analytic details it is possible to reduce the variance in the clinical setting to a level where patterns of gene expression are informative among different healthy human subjects, and can be studied with confidence in human disease.




Related Links:
Washington University School of Medicine

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.